Healthcare provider profile · identity verified

Karissa Hare, FNP-C

Nurse Practitioner · ROANOKE, VA · NPI 1275105132

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	244	39
Atorvastatin Calcium	Atorvastatin Calcium	236	46
Furosemide	Furosemide	206	50
Levothyroxine Sodium	Levothyroxine Sodium	195	35
Mirtazapine	Mirtazapine	161	23
Sertraline Hcl	Sertraline Hcl	159	33
Metformin Hcl	Metformin Hcl	155	26
Amlodipine Besylate	Amlodipine Besylate	153	28
Trazodone Hcl	Trazodone Hcl	149	38
Lisinopril	Lisinopril	128	24
Metoprolol Succinate	Metoprolol Succinate	127	18
Trulicity	Dulaglutide	123	13
Losartan Potassium	Losartan Potassium	107	18
Lorazepam	Lorazepam	99	23
Quetiapine Fumarate	Quetiapine Fumarate	99	16
Oxycodone Hcl	Oxycodone Hcl	95	37
Donepezil Hcl	Donepezil Hcl	91	18
Metoprolol Tartrate	Metoprolol Tartrate	90	22
Potassium Chloride	Potassium Chloride	89	20
Tamsulosin Hcl	Tamsulosin Hcl	87	14
Omeprazole	Omeprazole	86	24
Memantine Hcl	Memantine Hcl	85	13
Eliquis	Apixaban	77	11
Pantoprazole Sodium	Pantoprazole Sodium	74	12
Hydrochlorothiazide	Hydrochlorothiazide	67	suppressed
Risperidone	Risperidone	67	17
Escitalopram Oxalate	Escitalopram Oxalate	66	15
Divalproex Sodium	Divalproex Sodium	56	11
Buspirone Hcl	Buspirone Hcl	54	12
Duloxetine Hcl	Duloxetine Hcl	54	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	54	11
Januvia	Sitagliptin Phosphate	50	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	49	49
Clopidogrel	Clopidogrel Bisulfate	48	11
Ondansetron Hcl	Ondansetron Hcl	48	25
Clonazepam	Clonazepam	47	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	46	12
Methenamine Hippurate	Methenamine Hippurate	45	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	45	suppressed
Pravastatin Sodium	Pravastatin Sodium	44	suppressed
Tramadol Hcl	Tramadol Hcl	42	11
Latanoprost	Latanoprost	40	suppressed
Levetiracetam	Levetiracetam	39	suppressed
Spironolactone	Spironolactone	38	suppressed
Clonidine Hcl	Clonidine Hcl	37	suppressed
Xarelto	Rivaroxaban	36	suppressed
Jardiance	Empagliflozin	35	suppressed
Nystatin	Nystatin	33	17
Aripiprazole	Aripiprazole	32	suppressed
Oxycontin	Oxycodone Hcl	32	suppressed
Baclofen	Baclofen	29	suppressed
Famotidine	Famotidine	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Lacosamide	Lacosamide	29	suppressed
Novolog Flexpen	Insulin Aspart	29	suppressed
Simvastatin	Simvastatin	29	suppressed
Warfarin Sodium	Warfarin Sodium	29	suppressed
Diclofenac Sodium	Diclofenac Sodium	28	11
Nitrofurantoin	Nitrofurantoin Macrocrystal	28	15
Mupirocin	Mupirocin	27	22
Cephalexin	Cephalexin	26	21
Metformin Hcl Er	Metformin Hcl	26	suppressed
Prednisone	Prednisone	26	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Fentanyl	Fentanyl	23	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	23	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	22	19
Lyumjev Kwikpen U-100	Insulin Lispro-Aabc	22	suppressed
Sucralfate	Sucralfate	22	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	21	18
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Erythromycin	Erythromycin Base	21	15
Nyamyc	Nystatin	21	17
Fenofibrate	Fenofibrate	18	suppressed
Olanzapine	Olanzapine	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Fluconazole	Fluconazole	17	suppressed
Prazosin Hcl	Prazosin Hcl	17	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	16	suppressed
Loperamide	Loperamide Hcl	16	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Morphine Sulfate Er	Morphine Sulfate	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Diazepam	Diazepam	14	suppressed
Flecainide Acetate	Flecainide Acetate	14	suppressed
Hydrocortisone	Hydrocortisone	14	14
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	12
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	14	suppressed
Xtampza Er	Oxycodone Myristate	14	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	13	suppressed
Doxepin Hcl	Doxepin Hcl	13	suppressed
Finasteride	Finasteride	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Digoxin	Digoxin	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Bumetanide	Bumetanide	11	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Gentamicin Sulfate	Gentamicin Sulfate	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error